Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor
Cancer Medicine · 2025
DOI: 10.1002/cam4.71039 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Ge Gao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, National Medical Products Administration key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China H…. Hauptthemen laut MEDLINE: Paclitaxel, Neoplasms, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Zhongsheng BioPharma Co. Ltd..
Abstract (Originalsprache)
Purpose
A novel paclitaxel delivery system has the potential to avoid the side effects associated with Cremophor EL and thus enhance therapeutic efficacy. Here, we report the results of a preclinical and phase I clinical study investigating ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel (PM‐paclitaxel).
Methods
In preclinical studies, A549, MDA‐MB‐231, and SKOV3 xenograft tumor models were developed. Various concentrations of ZSYY001 were administered, and tumor growth and body weight were measured. Sprague–Dawley (SD) rats and Beagle dogs were used to evaluate the toxicity. In the phase I study, a dose‐escalation study using a 3 + 3 design was conducted in patients with solid tumors. The PM‐paclitaxel dose was escalated from 175 mg/m 2 to 390 mg/m 2 . PM‐paclitaxel was intravenously administered over 3 h every 21 days without any premedication. This study was registered with number CTR20210347.
Results
Preclinical studies showed that ZSYY001 significantly inhibited tumor growth without causing weight loss. In the phase I study, all patients were evaluable for toxicity and pharmacokinetic analysis, and 18 patients were evaluable for tumor response. Acute hypersensitivity reactions were not observed. Anemia and hair loss were the most common toxicities. Dose‐limiting toxicity events were not observed at any dose levels. Dose escalation to 390 mg/m 2 did not identify a maximum‐tolerated dose. There were two partial responses (11.11%) and seven cases of stable disease (38.89%) among the 18 patients, five of whom had prior exposure to paclitaxel chemotherapy. The paclitaxel area under the curve and peak paclitaxel concentration suggest that PM‐paclitaxel does not exhibit linear pharmacokinetics.
Conclusions
ZSYY001 was safe and well tolerated without additional toxicity and exhibited desirable antitumor activity, making it a promising treatment. Trial Registration CTR20210347
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Trial Center, National Medical Products Administration key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Guangdong Zhongsheng Pharmaceutical Co. Ltd., Guangzhou, Guangdong, China.
- Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
- Department of Phase 1 Trials Center, North Guangdong People's Hospital, Guangzhou, Guangdong, China.
- Department of Oncology, North Guangdong People's Hospital, Guangzhou, China.
ORCID-Profile: Pei Shu, Yongsheng Wang
Förderung
- Guangdong Zhongsheng BioPharma Co. Ltd.
Zitieren
APA
Gao, G., Shu, P., Tan, Y., Zheng, T., Fan, W., Lu, L., Zhou, H., Wang, Z., Liu, L., Liu, Z., & Wang, Y. (2025). Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor. Cancer Medicine. https://doi.org/10.1002/cam4.71039
Vancouver
Gao G, Shu P, Tan Y, Zheng T, Fan W, Lu L, et al. Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor. Cancer Medicine. 2025. doi:10.1002/cam4.71039
BibTeX
@article{Gao2025,
author = {Gao, Ge and Shu, Pei and Tan, Youzhen and Zheng, Tongsen and Fan, Wenmao and Lu, Luding and Zhou, Huan and Wang, Zishu and Liu, Ling and Liu, Zhiqiang and Wang, Yongsheng},
title = {Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71039}
}
EUVIMED